Egrifta SV (tesamorelin): Uses, Dosage, Side Effects (2026)
Egrifta SV is FDA-approved by Theratechnologies for the indication below. This page is clinically reviewed.
TL;DR / Quick Facts
Egrifta SV (tesamorelin) is FDA-approved for HIV-associated lipodystrophy (excess visceral abdominal fat). Manufacturer: Theratechnologies. First FDA approval: 2010-11-10. Boxed warning: no. REMS: no. This page summarizes the FDA label and adds a Medriva editorial stance.
What Egrifta SV is
Egrifta SV is a stabilized GHRH analog for HIV lipodystrophy.
FDA-approved indication(s)
- HIV-associated lipodystrophy (excess visceral abdominal fat)
Mechanism of action
See the FDA label (linked in references).
Typical dosing
Per the FDA label. The starting dose, escalation, and target dose vary by indication and patient factors. A clinician must determine the appropriate dose. Do not self-titrate.
Side effects and risks
- Common: see the FDA label.
- Boxed warning: none.
- Serious: see the FDA label.
Regulatory status
- FDA approval date: 2010-11-10
- Manufacturer: Theratechnologies
- Boxed warning: absent
- REMS: absent
- Compounded availability: see compounded vs brand GLP-1 explainer where relevant.
Cost and access
By prescription. See cost pages for indication-specific pricing.
Medriva editorial stance
We describe the FDA label. We do not promote off-label use, compounded versions as substitutes, or celebrity tie-ins. We do recommend following the labeled protocol under clinical supervision.
Frequently Asked Questions
Is Egrifta SV FDA-approved?
Yes. Approval date: 2010-11-10.
What is the boxed warning?
Egrifta Sv does not have a boxed warning.
Is there a REMS?
No.
References
- FDA label for Egrifta SV (most current revision) — accessdata.fda.gov
Related pages
- Semaglutide profile (where applicable)
- Tirzepatide profile (where applicable)
- Use-case hub (where applicable)
- Cost & access
---
Disclaimer: The content above summarizes the FDA label. The label is the authoritative source. Medriva does not sell Egrifta SV. Always consult a licensed clinician.
Evidence and clinical context
Egrifta SV (tesamorelin): Uses, Dosage, Side Effects should be read as a clinical reference topic rather than a product recommendation. Medriva prioritizes human studies, regulator documents, prescribing information, inspection records, and transparent methodology over testimonials or marketing claims. If evidence is preliminary, indirect, or based mostly on mechanistic reasoning, the page should not be interpreted as proof of benefit.
When reviewing this topic, the strongest page is the one that separates mechanism, human evidence, regulatory status, adverse effects, access, and monitoring. A promising mechanism does not automatically make a peptide clinically appropriate.
For non-profile pages, the key questions are whether the claim relies on primary sources, whether the evidence applies to the reader's actual situation, and whether the page distinguishes approved medicines from compounded or research-use products.
Safety and regulatory notes
Safety review starts with the most conservative assumption: peptides and GLP-1 therapies can have meaningful adverse effects, contraindications, drug interactions, and quality-control risks. Gastrointestinal symptoms, allergic reactions, pregnancy considerations, endocrine effects, gallbladder or pancreatic symptoms, and medication interactions require clinician input rather than internet-based decision-making.
Regulatory context still matters even when the main topic is clinical. FDA approval, compounding status, research-use marketing, state rules, and sports restrictions can change how a reader should interpret access claims. The Peptide Tracker is the best starting point for current FDA, OIG, WADA, NABP, and trade-body source updates that may affect this topic.
How to use this page
Use this page to prepare better questions for a licensed clinician or pharmacist. A useful conversation includes the reason the peptide is being considered, current diagnoses, pregnancy status, medication list, prior adverse reactions, lab history, and whether the product is FDA-approved for the intended use. Medriva does not sell peptides, does not rank vendors, and does not provide individualized dosing instructions.
If a page mentions cost, access, compounding, or telehealth, treat those sections as background context. Coverage, supply, and legality can vary by state, indication, product status, and time. Confirm details with the prescribing clinician, pharmacist, insurer, and current regulator sources before acting.
